top of page
GCC vs. Maghreb: Why Treating MENA as a Single Market Is the Most Expensive Mistake in Pharma BD
GCC, Levant, Maghreb, three distinct regulatory and commercial realities within MENA. Discover why sub-regional precision determines market entry success, and what treating MENA as one market actually costs. | Nexus Pharmalink
4 min read
The European Pharmaceutical Market: A Strategic Window for MENA Companies Seeking Innovation Access
Europe holds 30% of the global pharma market and is a primary source of in-licensing opportunities for MENA companies. Discover why EMA approval status changes the regulatory equation for MENA submissions. | Nexus Pharmalink
4 min read
Why Saudi Vision 2030 Has Permanently Changed the Rules of MENA Pharmaceutical Market Entry
Saudi Vision 2030 permanently changed MENA pharma entry rules, technology transfer is now commercially superior to pure licensing. Learn what this means for your market entry strategy. | Nexus Pharmalink
3 min read
bottom of page